IP-rich Japanese companies may face new competition issues in Europe: CJEU’s decision in AstraZeneca
Japanese companies that enjoy a dominant position in a particular market in Europe are likely to be aware that they are subject to high standards of competitive behaviour, and must not abuse their dominant position lest they be deemed to have infringed Article 102 of the Treaty on the Functioning of the European Union (“TFEU”). … Read more